Severe Fever with Thrombocytopenia Syndrome Virus 2025
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Human Virology and Viral Diseases".
Deadline for manuscript submissions: 31 May 2025 | Viewed by 586
Special Issue Editor
Special Issue Information
Dear Colleagues,
We are still facing a global pandemic of coronavirus disease 2019 (COVID-19) caused by a novel coronavirus, severe acute respiratory syndrome virus coronavirus 2 (SARS-CoV-2). In 2013–2016, there was a huge outbreak of Ebola virus disease (EVD) in West Africa. The global spread of Mpox virus infections, which are endemic to Central and Western Africa, began in 2022 as a form of sexually transmitted disease. It was found that Mpox virus had spilled over from some species of rodents to humans. In the last 30 years, we have identified many novel infectious diseases with a high case fatality rate caused by viruses that spilled over from animals to humans. Severe fever with thrombocytopenia syndrome (SFTS) is one of these emerging viral infections that should be included in this category.
SFTS was reported to be a novel bunyavirus infection by Chinese scientists in 2011. SFTS is a tick-borne viral infection with high morbidity and mortality. SFTS was discovered to be endemic to Japan and South Korea in 2012. The case fatality rate in patients with SFTS in Japan is reported to be approximately 30%. The vectors, which play a role in transmitting the causative agent, Bandavirus dabieense (formally SFTS virus (SFTSV)), include Haemaphysalis longicornis, amongst others. Furthermore, patients with SFTS have been identified in Taiwan, Vietnam, and Thailand, indicating that the endemic area of SFTS is much wider than previously thought.
SFTSV is circulating in nature in Asia including China, Korea, and Japan through transmission of the virus between some species of ticks and mammals. The evidence indicates that SFTS has occurred in the past and will continue to occur in the future. We cannot escape from the risk of being infected with SFTSV, and we are unable to eradicate this virus.
More than 10 years have passed since the discovery of SFTS. We have had some achievements in the elucidation of SFTSV characteristics, clarification of SFTS epidemiology, pathophysiology of SFTS in patients, mechanisms of SFTSV maintenance in nature, and in the development of specific treatments and vaccines. In this Special Issue, we aim to collect recent research and achievements in the study on SFTSV and its infection. We welcome submissions addressing topics including but not limited to the following:
- New topics in SFTSV virology;
- Epidemiology of SFTS;
- Clinical aspects and pathophysiology of SFTS in patients;
- Diagnostics of SFTS in humans and animals;
- SFTS as a zoonotic disease;
- Mechanisms of SFTSV maintenance in nature;
- Development of specific treatments for patients with SFTS;
- Development of vaccines against SFTS;
- Other topics specific to SFTS.
Dr. Masayuki Saijo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- SFTS
- SFTSV
- emerging viral infections
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
Related Special Issues
- Severe Fever with Thrombocytopenia Syndrome Virus in Viruses (14 articles)
- Severe Fever with Thrombocytopenia Syndrome Virus 2022 in Viruses (10 articles)
- Severe Fever with Thrombocytopenia Syndrome Virus 3.0 in Viruses (8 articles)
